Skip to main content
Clinical Trials/NCT05776602
NCT05776602
Recruiting
Not Applicable

Fast Brain MRI in Children With Suspected or Confirmed Brain Tumor

Karolinska University Hospital1 site in 1 country50 target enrollmentMay 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Magnetic Resonance Imaging
Sponsor
Karolinska University Hospital
Enrollment
50
Locations
1
Primary Endpoint
Diagnostic performance
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study aims to assess the diagnostic performance of a new fast MRI sequence named Neuromix compared to routine clinical MRI for brain tumor in pediatric patients

Detailed Description

The study aims to assess the diagnostic performance of fast MR sequence for the radiological evaluation of brain tumor in comparison to routine clinical MRI (or reference standard) in a pediatric population. The primary outcome is the depiction and characterization of normal brain, brain tumor pathology and incidental findings. Sensitivity, specificity, AUC and intra-/ interreader agreement for the diagnostic performance of Neuromix compared to cMRI will be obtained. Correlation of results between methods will be calculated. Secondary outcomes will also include the assessment of diagnostic image quality and image artifacts. The study population will consist of subjects aged 0-18 with a suspected or diagnosed brain tumor referred for routine MRI examination of the brain. Study subjects will be investigated during the same day at 3T MR with Neuromix sequence in addition to the routine MRI examination. Volume measurements will be compared.

Registry
clinicaltrials.gov
Start Date
May 1, 2023
End Date
December 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Karolinska University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Anna Falk Delgado

MD, associate professor

Karolinska University Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 0-18 years.
  • Pediatric subjects with diagnosed or suspected brain tumor
  • Referral routine MRI study.

Exclusion Criteria

  • MRI planned without sedation
  • Aborted MR exam
  • Unstable patient

Outcomes

Primary Outcomes

Diagnostic performance

Time Frame: Through study completion, an average of 1 year

AUC, area under the curve for the comparison of the new method against the reference standard

Secondary Outcomes

  • Imaging quality(through study completion, an average of 1 year)
  • Agreement(through study completion, an average of 1 year)
  • Sensitivity(through study completion, an average of 1 year)
  • Imaging artifacts(through study completion, an average of 1 year)
  • Correlation(through study completion, an average of 1 year)
  • Specificity(through study completion, an average of 1 year)

Study Sites (1)

Loading locations...

Similar Trials